The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations
Open accessAbstract
BACKGROUND: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene containing a premature termination signal cause a deficiency or absence of functional chloride-channel activity. Aminoglycoside antibiotics can suppress premature termination codons, thus permitting translation to continue to the normal end of the transcript. We assessed whether topical administration of gentamicin to the nasal epithelium of patients with cystic fibrosis could result in the expression of functional CFTR channels. METHODS: In a double-blind, placebo-controlled, crossover trial, patients with stop mutations in CFTR or patients homozygous for the DeltaF508 mutation received two drops containing gentamicin (0.3 percent, or 3 mg per milliliter) or placebo in each nostril three times daily for two consecutive periods of 14 days. Nasal potential difference was measured at base line and after each treatment period. Nasal epithelial cells were obtained before and after gentamicin treatment from patients carrying stop mutations, and the C-terminal of surface CFTR was stained. RESULTS: Gentamicin treatment caused a significant reduction in basal potential difference in the 19 patients carrying stop mutations (from -45+/-8 to -34+/-11 mV, P=0.005) and a significant response to chloride-free isoproterenol solution (from 0+/-3.6 to -5+/-2.7 mV, P<0.001). This effect of gentamicin on nasal potential difference occurred both in patients who were homozygous for stop mutations and in those who were heterozygous, but not in patients who were homozygous for DeltaF508. After gentamicin treatment, a significant increase in peripheral and surface staining for CFTR was observed in the nasal epithelial cells of patients carrying stop mutations. CONCLUSIONS: In patients with cystic fibrosis who have premature stop codons, gentamicin can cause translational "read through," resulting in the expression of full-length CFTR protein at the apical cell membrane, and thus can correct the typical electrophysiological abnormalities caused by CFTR dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Design and Analysis of Clinical Experiments
Fleiss, J. L. (1999) · Wiley eBooks · doi:10.1002/9781118032923 · Cited by 4,819
Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E., & Sweeney, H. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7866 · Cited by 585
Correlation between Genotype and Phenotype in Patients with Cystic Fibrosis
(1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291804 · Cited by 562
Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
Howard, M., Frizzell, R. A., & Bedwell, D. M. (1996) · Nature Medicine · doi:10.1038/nm0496-467 · Cited by 493
Highsmith, W. E., Burch, L. H., Zhou, Z., Olsen, J. C., Boat, T. E., Spock, A., Gorvoy, J. D., Quittell, L., Friedman, K. J., Silverman, L. M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311503 · Cited by 441
Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
Bedwell, D. M., Kaenjak, A., Benos, D. J., Bebok, Z., Bubien, J. K., Hong, J., Tousson, A., Clancy, J. P., & Sorscher, E. J. (1997) · Nature Medicine · doi:10.1038/nm1197-1280 · Cited by 343
Self-citationRUBENSTEIN, R. C., & ZEITLIN, P. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9706088 · Cited by 340
Knowles, M. R., Paradiso, A. M., & Boucher, R. C. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.4-445 · Cited by 308
Bonetti, B., Fu, L., Moon, J., & Bedwell, D. M. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0438 · Cited by 307
Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations
Wagner, K. R., Hamed, S., Hadley, D. W., Gropman, A. L., Burstein, A. H., Escolar, D. M., Hoffman, E. P., & Fischbeck, K. H. (2001) · Annals of Neurology · doi:10.1002/ana.1023 · Cited by 272
Cited by
Rowe, S. M., Miller, S., & Sorscher, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043184 · Cited by 1,398
Lubos, E., Loscalzo, J., & Handy, D. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3586 · Cited by 1,280
PTC124 targets genetic disorders caused by nonsense mutations
Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., et al. (2007) · Nature · doi:10.1038/nature05756 · Cited by 1,137
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Self-citationEffect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 807
CFTR Function and Prospects for Therapy
Riordan, J. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142532 · Cited by 610
Nonsense-mediated decay approaches the clinic
Holbrook, J. A., Neu-Yilik, G., Hentze, M. W., & Kulozik, A. E. (2004) · Nature Genetics · doi:10.1038/ng1403 · Cited by 596
Ratjen, F., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 546
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation
Olson, T. M., Alekseev, A. E., Liu, X. K., Park, S., Zingman, L. V., Bienengraeber, M., Sattiraju, S., Ballew, J. D., Jahangir, A., & Terzic, A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl143 · Cited by 491
Chloride channels as drug targets
Verkman, A. S., & Galietta, L. J. V. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2780 · Cited by 469
Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M., Nissim-Rafinia, M., Blau, H., Rivlin, J., Aviram, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61168-x · Cited by 403
Self-citationOrganizing Principles of Mammalian Nonsense-Mediated mRNA Decay
Popp, M. W.-L., & Maquat, L. E. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-111212-133424 · Cited by 372
DNAH5 Mutations Are a Common Cause of Primary Ciliary Dyskinesia with Outer Dynein Arm Defects
Hornef, N., Olbrich, H., Horvath, J., Zariwala, M. A., Fliegauf, M., Loges, N. T., Wildhaber, J., Noone, P. G., Kennedy, M., Antonarakis, S. E., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200601-084oc · Cited by 353
Genetic Defects in Ciliary Structure and Function
Zariwala, M. A., Knowles, M. R., & Omran, H. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.040705.141301 · Cited by 312
Therapeutics Based on Stop Codon Readthrough
Keeling, K. M., Xue, X., Gunn, G., & Bedwell, D. M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153527 · Cited by 306
Linde, L., Boelz, S., Nissim-Rafinia, M., Oren, Y. S., Wilschanski, M., Yaacov, Y., Virgilis, D., Neu-Yilik, G., Kulozik, A. E., Kerem, E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28523 · Cited by 300
Self-citationNew developments in aminoglycoside therapy and ototoxicity
Xie, J., Talaska, A. E., & Schacht, J. (2011) · Hearing Research · doi:10.1016/j.heares.2011.05.008 · Cited by 287
The genetic basis of non-syndromic intellectual disability: a review
Kaufman, L., Ayub, M., & Vincent, J. B. (2010) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-010-9055-2 · Cited by 279
Du, M., Liu, X., Welch, E. M., Hirawat, S., Peltz, S. W., & Bedwell, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711795105 · Cited by 256
Cystic fibrosis: a clinical view
Castellani, C., & Assael, B. M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2393-9 · Cited by 254
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
JOHNSON, A., WANG, D., & SADEE, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.001 · Cited by 97
Succinic Semialdehyde Dehydrogenase Deficiency: An Update
Didiasova, M., Banning, A., Brennenstuhl, H., Jung-Klawitter, S., Cinquemani, C., Opladen, T., & Tikkanen, R. (2020) · Cells · doi:10.3390/cells9020477 · Cited by 52
Rapid therapeutic advances in CFTR modulator science
Clancy, J. P. (2018) · Pediatric Pulmonology · doi:10.1002/ppul.24157 · Cited by 52
New Therapies to Correct the Cystic Fibrosis Basic Defect
Bergeron, C., & Cantin, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126193 · Cited by 22
Miyoshi, T., Vishwasrao, H. D., Belyantseva, I. A., Miyoshi, J., Sajeevadathan, M., Ishibashi, Y., Adadey, S. M., Harada, N., Shroff, H., & Friedman, T. B. (2025) · Nature Communications · doi:10.1038/s41467-025-63102-0 · Cited by 1
Metadata
- Authors
- Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., Aviram, M., Bdolah-Abram, T., Bebok, Z., Shushi, L., Kerem, B., & Kerem, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-10-09
- Volume
- 349
- Issue
- 15
- Pages
- 1433-1441
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158010208
- Cited by
- 503
- References
- 24
- FWCI
- 25.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.